India
· Delayed Price · Currency is INR Remus Pharmaceuticals Statistics
Total Valuation
Remus Pharmaceuticals has a market cap or net worth of INR 13.90 billion. The enterprise value is 13.87 billion.
| Market Cap | 13.90B |
| Enterprise Value | 13.87B |
Important Dates
The last earnings date was Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | Nov 19, 2024 |
Share Statistics
Remus Pharmaceuticals has 5.89 million shares outstanding. The number of shares has increased by 8.32% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 5.89M |
| Shares Change (YoY) | +8.32% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 69.86% |
| Owned by Institutions (%) | n/a |
| Float | 1.72M |
Valuation Ratios
The trailing PE ratio is 46.50.
| PE Ratio | 46.50 |
| Forward PE | n/a |
| PS Ratio | 3.05 |
| PB Ratio | 13.83 |
| P/TBV Ratio | 15.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 46.40 |
| EV / Sales | 3.04 |
| EV / EBITDA | 32.70 |
| EV / EBIT | 33.50 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.82, with a Debt / Equity ratio of 0.17.
| Current Ratio | 1.82 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 0.52 |
| Debt / FCF | n/a |
| Interest Coverage | 36.41 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 95.10M |
| Profits Per Employee | 6.23M |
| Employee Count | 48 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +33.67% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +33.67% |
| 50-Day Moving Average | 2,518.42 |
| 200-Day Moving Average | 2,154.39 |
| Relative Strength Index (RSI) | 38.37 |
| Average Volume (20 Days) | 3,678 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Remus Pharmaceuticals had revenue of INR 4.57 billion and earned 299.01 million in profits. Earnings per share was 50.73.
| Revenue | 4.57B |
| Gross Profit | 738.12M |
| Operating Income | 392.45M |
| Pretax Income | 458.53M |
| Net Income | 299.01M |
| EBITDA | 402.67M |
| EBIT | 392.45M |
| Earnings Per Share (EPS) | 50.73 |
Balance Sheet
The company has 459.93 million in cash and 208.45 million in debt, giving a net cash position of 251.48 million or 42.68 per share.
| Cash & Cash Equivalents | 459.93M |
| Total Debt | 208.45M |
| Net Cash | 251.48M |
| Net Cash Per Share | 42.68 |
| Equity (Book Value) | 1.23B |
| Book Value Per Share | 170.55 |
| Working Capital | 769.59M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 16.17%, with operating and profit margins of 8.60% and 6.55%.
| Gross Margin | 16.17% |
| Operating Margin | 8.60% |
| Pretax Margin | 10.04% |
| Profit Margin | 6.55% |
| EBITDA Margin | 8.82% |
| EBIT Margin | 8.60% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 0.08%.
| Dividend Per Share | 2.00 |
| Dividend Yield | 0.08% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -8.32% |
| Shareholder Yield | -8.24% |
| Earnings Yield | 2.15% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on June 6, 2024. It was a forward split with a ratio of 4.
| Last Split Date | Jun 6, 2024 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |